A novel genetic medicine platform focused on precise, durable, and safe gene modifications within blood stem cells has just landed $2.6M in pre-seed funding. Immitra Bio GmbH, the company behind this pioneering technology, is developing an innovative approach to genetic medicine.
The startup's platform is specifically designed to enable these modifications within blood stem cells, a critical step that aims to lay the foundation for scalable, curative in-vivo therapies.


















